臨床検査67巻9号

2023年09月発行

今月の特集 COVID-19と臨床検査—得られた知見を今後の医療に活かす

COVID-19と凝固線溶検査

著者： 山田真也¹ 朝倉英策¹

所属機関： ¹金沢大学附属病院血液内科

ページ範囲：P.964 - P.971

Point

●通常，感染症に合併する播種性血管内凝固（DIC）は“線溶抑制型”である．

●重症新型コロナウイルス感染症（COVID-19）では“線溶亢進型”DICを合併することがある．

●重症COVID-19における線溶亢進型DICは突然の経過で発症する．

●凝固線溶検査を的確に行うことで，DIC病型の突然の変化に気付くことが可能である．

参考文献

1）Tang N, Li D, Wang X, et al：Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost　18：844-847，2020

2）Zhang L, Yan X, Fan Q, et al：D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost　18：1324-1329，2020

3）Li Y, Zhao K, Wei H, et al：Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol　190：e24-e27，2020

4）Choi JJ, Wehmeyer GT, Li HA, et al：D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19. Thromb Res　196：318-321，2020

5）Long H, Nie L, Xiang X, et al：D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. Biomed Res Int　2020：6159720，2020

6）Gazzaruso C, Paolozzi E, Valenti C, et al：A possible link with obesity. Nutr Metab Cardiovasc Dis　30：1914-1919，2020

7）Xu X, Feng Y, Jia Y, et al：Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis. Thromb Res　218：83-98，2022

8）Bazzan M, Montaruli B, Sciascia S, et al：Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med　15：861-863，2020

9）石倉宏恭，丸山隼一，入江悠平，他：重症新型コロナウィルス感染症（COVID-19）の凝固線溶系異常の特徴Case series．日血栓止血会誌　31：398-408，2020

10）Lawler PR, Goligher EC, Berger JS, et al：Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med　385：790-802，2021

11）Goligher EC, Bradbury CA, McVerry BJ, et al：Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med　385：777-789，2021

12）Yamada S, Asakura H：Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. Int J Mol Sci　23：3338，2022

13）Yamada S, Asakura H：Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations. Int J Hematol　113：15-23，2021

14）Yamada S, Asakura H：Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm. Int J Mol Sci　23：1296，2022

15）Asakura H：Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care　2：20，2014

16）Wang J, Hajizadeh N, Moore EE, et al：Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost　18：1752-1755，2020

17）Maier CL, Sarker T, Szlam F, et al：COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography. J Thromb Thrombolysis　52：766-771，2021

18）Jin X, Duan Y, Bao T, et al：The values of coagulation function in COVID-19 patients. PLoS One　15：e0241329，2020

19）Pavord ID, Holliday M, Reddel HK, et al：Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med　8：671-680，2020

20）McGonagle D, O'Donnell JS, Sharif K, et al：Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol　2：e437-e445，2020

21）Asakura H, Ogawa H：Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC. J Intensive Care　8：71，2020

22）山田真也，朝倉英策：COVID-19関連血栓症の治療成績向上のために：線溶評価の重要性．臨血　63，471-480，2022

23）Fujii S, Hitomi Y：New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta　661：342-345，1981

24）Asakura H, Ogawa H：Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost　18：1521-1522，2020

25）Asakura H, Ogawa H：COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol　113：45-57，2021

26）Yamamoto M, Kiso M, Sakai-Tagawa Y, et al：The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Viruses　12：629，2020

27）Ragia G, Manolopoulos VG：Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol　76：1623-1630，2020

28）Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, et al：Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J Thromb Haemost　19：3080-3089，2021